JP6449844B2 - 神経学的症状を治療するための脳への薬物の送達のための装置、システムおよび方法 - Google Patents
神経学的症状を治療するための脳への薬物の送達のための装置、システムおよび方法 Download PDFInfo
- Publication number
- JP6449844B2 JP6449844B2 JP2016501720A JP2016501720A JP6449844B2 JP 6449844 B2 JP6449844 B2 JP 6449844B2 JP 2016501720 A JP2016501720 A JP 2016501720A JP 2016501720 A JP2016501720 A JP 2016501720A JP 6449844 B2 JP6449844 B2 JP 6449844B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- diffusion chamber
- brain
- diffusion
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims description 261
- 229940079593 drug Drugs 0.000 title claims description 255
- 210000004556 brain Anatomy 0.000 title claims description 162
- 238000000034 method Methods 0.000 title description 52
- 206010060860 Neurological symptom Diseases 0.000 title description 7
- 238000009792 diffusion process Methods 0.000 claims description 279
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 91
- 239000008188 pellet Substances 0.000 claims description 53
- 239000007787 solid Substances 0.000 claims description 41
- 206010015037 epilepsy Diseases 0.000 claims description 38
- 230000002861 ventricular Effects 0.000 claims description 32
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 31
- 229960003883 furosemide Drugs 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 25
- 239000012530 fluid Substances 0.000 claims description 22
- 239000012528 membrane Substances 0.000 claims description 18
- 230000007480 spreading Effects 0.000 claims description 18
- 238000003892 spreading Methods 0.000 claims description 18
- 206010010904 Convulsion Diseases 0.000 description 120
- 238000012377 drug delivery Methods 0.000 description 65
- 238000001514 detection method Methods 0.000 description 40
- 230000000926 neurological effect Effects 0.000 description 38
- 230000005684 electric field Effects 0.000 description 34
- 230000002159 abnormal effect Effects 0.000 description 33
- 210000001519 tissue Anatomy 0.000 description 32
- 208000024891 symptom Diseases 0.000 description 27
- 230000000008 neuroelectric effect Effects 0.000 description 24
- 210000005013 brain tissue Anatomy 0.000 description 23
- 238000003860 storage Methods 0.000 description 23
- 239000000463 material Substances 0.000 description 21
- 238000007917 intracranial administration Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 230000001766 physiological effect Effects 0.000 description 18
- 230000001054 cortical effect Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 15
- 238000004422 calculation algorithm Methods 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000003792 electrolyte Substances 0.000 description 12
- 239000002171 loop diuretic Substances 0.000 description 12
- 229920001296 polysiloxane Polymers 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 239000004814 polyurethane Substances 0.000 description 11
- 229920002635 polyurethane Polymers 0.000 description 11
- 208000003443 Unconsciousness Diseases 0.000 description 10
- 239000003844 drug implant Substances 0.000 description 10
- 210000003128 head Anatomy 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000005020 polyethylene terephthalate Substances 0.000 description 10
- 210000003625 skull Anatomy 0.000 description 10
- 208000019695 Migraine disease Diseases 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 108020003264 Cotransporters Proteins 0.000 description 8
- 102000034534 Cotransporters Human genes 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 231100000862 numbness Toxicity 0.000 description 8
- 208000004044 Hypesthesia Diseases 0.000 description 7
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 208000034783 hypoesthesia Diseases 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000003140 lateral ventricle Anatomy 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 206010027599 migraine Diseases 0.000 description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229920000249 biocompatible polymer Polymers 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 229920004934 Dacron® Polymers 0.000 description 4
- 239000004642 Polyimide Substances 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002059 diagnostic imaging Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 208000028329 epileptic seizure Diseases 0.000 description 4
- 238000010304 firing Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- -1 polyethylene terephthalate Polymers 0.000 description 4
- 229920001721 polyimide Polymers 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 229920002614 Polyether block amide Polymers 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007177 brain activity Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000000537 electroencephalography Methods 0.000 description 3
- 230000001037 epileptic effect Effects 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 210000004055 fourth ventricle Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000000337 motor cortex Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 3
- 229910001000 nickel titanium Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920005594 polymer fiber Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000036387 respiratory rate Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000000211 third ventricle Anatomy 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010083687 Ion Pumps Proteins 0.000 description 2
- 108091006671 Ion Transporter Proteins 0.000 description 2
- 102000037862 Ion Transporter Human genes 0.000 description 2
- 102000047724 Member 2 Solute Carrier Family 12 Human genes 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108091006620 SLC12A2 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004289 cerebral ventricle Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 210000002987 choroid plexus Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000019692 hotdogs Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 239000012781 shape memory material Substances 0.000 description 2
- 210000001154 skull base Anatomy 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 208000003078 Generalized Epilepsy Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 230000005355 Hall effect Effects 0.000 description 1
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 102000006391 Ion Pumps Human genes 0.000 description 1
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 108010074941 Sodium-Potassium-Chloride Symporters Proteins 0.000 description 1
- 102000008145 Sodium-Potassium-Chloride Symporters Human genes 0.000 description 1
- 101000640897 Squalus acanthias Solute carrier family 12 member 2 Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009507 drug disintegration testing Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000009429 electrical wiring Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011705 epilepsy animal model Methods 0.000 description 1
- 230000008579 epileptogenesis Effects 0.000 description 1
- 230000002397 epileptogenic effect Effects 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001990 hyperexcitatory effect Effects 0.000 description 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229940063711 lasix Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000875 loss of motor control Toxicity 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 239000005458 thiazide-like diuretic Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/008—Strength or flexibility characteristics of the catheter tip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3925—Markers, e.g. radio-opaque or breast lesions markers ultrasonic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3966—Radiopaque markers visible in an X-ray image
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M2025/0042—Microcatheters, cannula or the like having outside diameters around 1 mm or less
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/008—Strength or flexibility characteristics of the catheter tip
- A61M2025/0081—Soft tip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0693—Brain, cerebrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36064—Epilepsy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Physiology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/827,468 US10507313B2 (en) | 2009-01-26 | 2013-03-14 | Apparatus, systems and methods for delivery of medication to the brain to treat neurological conditions |
| US13/827,468 | 2013-03-14 | ||
| PCT/US2014/025018 WO2014159757A2 (en) | 2013-03-14 | 2014-03-12 | Apparatus, systems and methods for delivery of medication to the brain to treat neurological condidtions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018030643A Division JP2018102951A (ja) | 2013-03-14 | 2018-02-23 | 神経学的症状を治療するための脳への薬物の送達のための装置、システムおよび方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515866A JP2016515866A (ja) | 2016-06-02 |
| JP2016515866A5 JP2016515866A5 (https=) | 2018-04-05 |
| JP6449844B2 true JP6449844B2 (ja) | 2019-01-09 |
Family
ID=51625613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501720A Expired - Fee Related JP6449844B2 (ja) | 2013-03-14 | 2014-03-12 | 神経学的症状を治療するための脳への薬物の送達のための装置、システムおよび方法 |
| JP2018030643A Pending JP2018102951A (ja) | 2013-03-14 | 2018-02-23 | 神経学的症状を治療するための脳への薬物の送達のための装置、システムおよび方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018030643A Pending JP2018102951A (ja) | 2013-03-14 | 2018-02-23 | 神経学的症状を治療するための脳への薬物の送達のための装置、システムおよび方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2968881B8 (https=) |
| JP (2) | JP6449844B2 (https=) |
| CN (1) | CN105377354B (https=) |
| AU (2) | AU2014244437B9 (https=) |
| WO (1) | WO2014159757A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2739431C (en) | 2008-10-01 | 2016-12-06 | Sherwin Hua | System and method for wire-guided pedicle screw stabilization of spinal vertebrae |
| US11331424B2 (en) | 2009-01-26 | 2022-05-17 | Incube Labs, Llc | Apparatus, systems and methods for delivery of medication to the brain to treat neurological conditions |
| US9919146B2 (en) | 2013-05-01 | 2018-03-20 | Sherwin Hua | Methods and systems for intraventricular brain stimulation |
| WO2018044933A1 (en) * | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| EP3654844A4 (en) * | 2017-07-21 | 2021-04-14 | Abbott Diabetes Care Inc. | DEVICES, SYSTEMS AND METHODS FOR DISPENSING SOLID FORMULATIONS |
| AU2018308115B2 (en) * | 2017-07-26 | 2023-12-14 | Neuraptive Therapeutics, Inc. | Device and method of creating a fluid containment field for administering therapeutics to a nerve |
| JP7101859B2 (ja) * | 2018-07-02 | 2022-07-15 | ミネトロニクス ニューロ インコーポレイテッド | 中枢神経系に沿って治療するためのシステム、カテーテル、および方法 |
| AU2020321382B2 (en) * | 2019-08-01 | 2024-08-22 | Theracle, Inc. | Intracranial delivery of medicinal solution |
| CN121512655A (zh) | 2019-11-27 | 2026-02-13 | 斯拜因23公司 | 治疗脊柱侧弯的系统、装置和方法 |
| IL299826A (en) | 2020-07-15 | 2023-03-01 | Cerebral Therapeutics Inc | A medical device with a non-filtered CSF withdrawal path |
| US12329930B2 (en) | 2020-09-29 | 2025-06-17 | Enclear Therapies, Inc. | Subarachnoid fluid management method and system |
| CN115105675B (zh) * | 2021-03-18 | 2025-12-05 | 上海微创神奕医疗科技有限公司 | 一种医疗装置 |
| KR20240049213A (ko) | 2021-05-12 | 2024-04-16 | 스파인23 인코포레이티드 | 척추뼈의 척추경 나사를 안정화시키기 위한 시스템 및 방법 |
| US20230200707A1 (en) * | 2021-12-29 | 2023-06-29 | Cerebral Therapeutics, Inc. | Ventricular drain or shunt asssembly with recording electrode |
| US12605537B2 (en) | 2022-02-15 | 2026-04-21 | Biogen Ma Inc. | Implantable medical device for use with or having recording electrode |
| GB202211580D0 (en) * | 2022-08-09 | 2022-09-21 | Cambridge Entpr Ltd | Implantable device |
| CN115591048B (zh) * | 2022-12-16 | 2023-03-21 | 北京泰杰伟业科技有限公司 | 脑组织给药系统 |
| US20240285854A1 (en) * | 2023-02-28 | 2024-08-29 | Enclear Therapies, Inc. | Csf therapeutic delivery system |
| CN119565004A (zh) * | 2024-11-14 | 2025-03-07 | 武汉衷华脑机融合科技发展有限公司 | 一种脑脊液置换装置 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4829070A (en) * | 1982-05-18 | 1989-05-09 | University Of Florida | Novel redox carriers for brain-specific drug delivery |
| US5152744A (en) * | 1990-02-07 | 1992-10-06 | Smith & Nephew Dyonics | Surgical instrument |
| US5846220A (en) * | 1996-04-30 | 1998-12-08 | Medtronic, Inc. | Therapeutic method for treatment of Alzheimer's disease |
| US6458118B1 (en) * | 2000-02-23 | 2002-10-01 | Medtronic, Inc. | Drug delivery through microencapsulation |
| US20050137579A1 (en) * | 2003-12-23 | 2005-06-23 | Medtronic, Inc. | Permeable membrane catheters, systems, and methods |
| US9186175B2 (en) * | 2004-10-28 | 2015-11-17 | Nico Corporation | Surgical access assembly and method of using same |
| US20090131857A1 (en) * | 2007-11-20 | 2009-05-21 | Mark Geiger | Method and apparatus for introducing a medicinal dose directly into a mammalian patient's cerebrospinal fluid |
| WO2012047931A1 (en) * | 2010-10-04 | 2012-04-12 | Massachusetts Institute Of Technology | Device for local drug delivery and treatment of cerebral edema and other brain-related diseases |
-
2014
- 2014-03-12 JP JP2016501720A patent/JP6449844B2/ja not_active Expired - Fee Related
- 2014-03-12 CN CN201480015066.6A patent/CN105377354B/zh not_active Expired - Fee Related
- 2014-03-12 WO PCT/US2014/025018 patent/WO2014159757A2/en not_active Ceased
- 2014-03-12 EP EP14774821.4A patent/EP2968881B8/en active Active
- 2014-03-12 AU AU2014244437A patent/AU2014244437B9/en not_active Ceased
-
2018
- 2018-02-23 JP JP2018030643A patent/JP2018102951A/ja active Pending
-
2019
- 2019-01-29 AU AU2019200557A patent/AU2019200557A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014159757A3 (en) | 2015-01-29 |
| AU2014244437B2 (en) | 2018-11-08 |
| EP2968881B1 (en) | 2019-05-01 |
| CN105377354A (zh) | 2016-03-02 |
| CN105377354B (zh) | 2019-03-26 |
| AU2019200557A1 (en) | 2019-02-14 |
| JP2018102951A (ja) | 2018-07-05 |
| EP2968881A2 (en) | 2016-01-20 |
| AU2014244437A1 (en) | 2015-09-24 |
| EP2968881B8 (en) | 2019-10-09 |
| EP2968881A4 (en) | 2016-12-14 |
| AU2014244437B9 (en) | 2019-05-02 |
| WO2014159757A2 (en) | 2014-10-02 |
| JP2016515866A (ja) | 2016-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6449844B2 (ja) | 神経学的症状を治療するための脳への薬物の送達のための装置、システムおよび方法 | |
| US10507313B2 (en) | Apparatus, systems and methods for delivery of medication to the brain to treat neurological conditions | |
| JP2016515866A5 (https=) | ||
| US20190209778A1 (en) | Apparatus, systems and methods for the treatment of neurological conditions | |
| CN104983417B (zh) | 用于探测脑中的异常神经电活动的装置 | |
| ES2566730T3 (es) | Sincronización de estimulación del nervio vago con el ciclo cardíaco de un paciente | |
| US20060025821A1 (en) | Methods and devices for renal nerve blocking | |
| US20100305664A1 (en) | Methods and Devices for Adrenal Stimulation | |
| JP2008508024A (ja) | 腎神経ブロッキング方法及び装置 | |
| US20140058372A1 (en) | Treatment for renal failure | |
| US20230372685A1 (en) | Acute cerebrospinal fluid management implant | |
| US11331424B2 (en) | Apparatus, systems and methods for delivery of medication to the brain to treat neurological conditions | |
| US9095713B2 (en) | Methods and systems for treating autism by decreasing neural activity within the brain | |
| AU2015200463A1 (en) | Method and apparatus for the detection of aberrant neural-electric activity | |
| EP2583717A2 (en) | Methods and devices for renal nerve blocking |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170308 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170308 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171102 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180201 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20180223 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180911 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181108 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181206 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6449844 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |